CórdobaSGandolfo CanoMAguadoM. Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. Allergy. 2012;67:1609-1611.
2.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
3.
EsfandiarpourIFarajzadehSRahnamaZFathabadiEAHeshmatkhahA.Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2012;51:1221-1225.
4.
AsteNPauMFerreliCBiggioP.Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate. Br J Dermatol. 1998;138:370-371.
5.
JeddiFCaumesEThellierMJauréguiberrySMazierDBuffetPA.Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg. 2009;80:939-940.
